Foundation sells $3.3B in Vertex drug royalties

The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3 billion for innovative drugs it helped develop with Vertex Pharmaceuticals Incorporated.

The rights were acquired by Royalty Pharma, which owns royalty rights to 40 pharmaceutical medicines.

The foundation plans to use the proceeds to expand research into therapies for cystic fibrosis, a deadly inherited illness that causes sticky mucus buildup in the lungs and other organs.

The foundation first approached executives at Vertex's predecessor company in 1998 about drug development possibilities. The nonprofit ultimately awarded more than $100 million to the company, culminating in the 2012 approval of Kalydeco, the first drug to treat the of .

The twice-a-day pill had sales of $371 million last year, according to the Cambridge, Massachusetts company.

Explore further

Drug approved to treat cystic fibrosis' root cause

© 2014 The Associated Press. All rights reserved.

Citation: Foundation sells $3.3B in Vertex drug royalties (2014, November 19) retrieved 31 May 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments